Genocea Biosciences (GNCA) Rating Lowered to Hold at Zacks Investment Research

Genocea Biosciences (NASDAQ:GNCA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, HC Wainwright set a $5.00 target price on shares of Genocea Biosciences and gave the stock a “buy” rating in a report on Thursday, August 2nd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $3.35.

Shares of NASDAQ:GNCA opened at $0.68 on Thursday. The firm has a market cap of $62.38 million, a price-to-earnings ratio of -0.34 and a beta of 1.14. Genocea Biosciences has a 1-year low of $0.49 and a 1-year high of $1.39. The company has a debt-to-equity ratio of 1.91, a quick ratio of 4.01 and a current ratio of 4.01.

Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, November 1st. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. As a group, equities research analysts anticipate that Genocea Biosciences will post -0.45 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System increased its holdings in shares of Genocea Biosciences by 166.6% in the 1st quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 78,469 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in shares of Genocea Biosciences in the 1st quarter worth about $177,000. LMR Partners LLP acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $175,000. DRW Securities LLC acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $205,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $343,000. 60.23% of the stock is currently owned by institutional investors and hedge funds.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Story: How to calculate compound interest

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply